Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
Using anonymous online semi‑structured interviews with 13 participants and Interpretive Phenomenological Analysis, this study found that users approached microdosing methodically as a self-directed attempt to support mental health and wellbeing and reported perceived cognitive, physical and social benefits, describing microdosing as a catalyst for positive change. The paper adds qualitative, experiential insight into the rationale and meaning of the microdosing phenomenon to inform future research on psychedelics and mental health.
Authors
- Ryan, R. S.
- Copello, A.
- Fox, A. P.
Published
Abstract
Background
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential methods. This research therefore aimed to explore the way that users make sense of microdosing psychedelics, with a particular focus on the experience of any perceived mental health or wellbeing changes.
Method
Participants were recruited via websites and online forums. An internet text-based, semi-structured interview was conducted anonymously with 13 participants regarding their experiences of microdosing psychedelic drugs. Interpretive Phenomenological Analysis was used to analyse the transcripts.
Results
Three superordinate themes were identified through the interviews: 1) Seeking a solution: Agency and rationale; 2) Microdosers as scientists; 3) Catalysing desirable and beneficial effects.
Conclusions
All participants approached microdosing methodically and with purpose. Participants reported that they had experienced beneficial effects of microdosing on their mental health, alongside cognitive, physical and social changes. By microdosing, participants reported that they had supported their own mental health and wellbeing, with microdosing described as a catalyst to achieving their aims in this area. This study provided additional knowledge and understanding of the experience, rationale and personal meaning of the microdosing phenomenon which can be used to inform future investigations in the areas of psychedelic use and mental health.
Research Summary of 'Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health'
Introduction
Interest in psychedelic drugs for therapeutic purposes has re-emerged after decades of prohibition, and a recent trend within that broader revival is microdosing: ingesting very small, repeated doses of classic serotonergic psychedelics such as LSD or psilocybin. Earlier research and large online communities report that people try microdosing to enhance performance, mood, creativity or to relieve symptoms, but empirical studies remain few and mixed. Some controlled studies have found short-term or task-specific effects, while web-based surveys and qualitative reports have described perceived improvements in wellbeing alongside possible placebo influences and occasional adverse effects. Overall, the literature leaves unclear why individuals elect to microdose, how they approach it, and what subjective mental health or wellbeing changes they experience. Ryan and colleagues aimed to explore how people who microdose make sense of the practice, with particular attention to perceived effects on mental health and wellbeing. To allow in-depth understanding of subjective meaning, the investigators used anonymous, internet-based semi-structured interviews and analysed the material using Interpretative Phenomenological Analysis (IPA), a method designed to examine lived experience and meaning-making. The study took a neutral stance toward microdosing and focused on participants who were microdosing specifically to support mental health or wellbeing rather than for other motives.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Ryan, R. S., Copello, A., & Fox, A. P. (2023). Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. BMC Psychiatry, 23(1). https://doi.org/10.1186/s12888-023-04628-9
References (14)
Papers cited by this study that are also in Blossom
Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)
Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Substance Use (2010)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · International Journal of Neuropsychopharmacology (2019)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Lea, T., Jungaberle, H., Schecke, H. et al. · Psychopharmacology (2020)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Show all 14 referencesShow fewer
Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Webb, M., Copes, H., Hendricks, P. S. · International Journal of Drug Policy (2019)
Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)
Cited By (2)
Papers in Blossom that reference this study
Modzelewski, S., Waszkiewicz, N., Lukasiewicz, K. et al. · Neuropharmacology (2025)
Oblak, A., Korošec Hudnikr, L., Levačić, A. et al. · OSF Preprints (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.